---
title: "First‑trimester maternal cfRNA (MaiRa) outperforms FMF combined screening for early‑onset preeclam"
id: "medrxiv-5-maternal-cell-free-rna-versus-combined-screening-for-first-trimester-prediction"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-maternal-cell-free-rna-versus-combined-screening-for-first-trimester-prediction"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# First‑trimester maternal cfRNA (MaiRa) outperforms FMF combined screening for early‑onset preeclam
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-maternal-cell-free-rna-versus-combined-screening-for-first-trimester-prediction
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This nested case‑control analysis compared first‑trimester maternal plasma **cell‑free RNA** (MaiRa) against the Fetal Medicine Foundation (**FMF**) combined screening for predicting **early‑onset preeclampsia** (EOPE; onset <34 weeks) in the same 126 pregnancies. - The cohort comprised 99 uncomplicated controls and 27 EOPE cases drawn from the prospective, multicentre PREMOM study across 14 Spanish tertiary hospitals (NCT04990141). - Discrimination (AUC) was higher for MaiRa than FMF (0.974 vs 0.900; P = .040) using stratified paired bootstrap analysis of receiver‑operator curves. - At fixed false‑positive rates, MaiRa achieved higher detection rates: at 5% FPR it detected 85.2% of EOPE versus 44.4% for FMF; at 10% FPR it detected 92.6% versus 70.4% for FMF. - Patient‑level discordance showed MaiRa reclassified 12 of 27 EOPE cases (44.4%) that FMF labeled low risk; many of these had less abnormal conventional first‑trimester profiles (fewer maternal risk factors, lower mean arterial pressure and lower uterine artery pulsatility index), yet 8 of those 12 later developed severe EOPE. - Implementation modelling indicated universal MaiRa screening maximized EOPE detection, while a contingent approach (FMF triage with reflex MaiRa testing) reduced molecular testing to 35.7% of pregnancies and maintained 77.8% sensitivity with 97.0% specificity. - Authors conclude MaiRa captures biological alterations not fully reflected by conventional first‑trimester screening and recommend further prospective evaluation in independent, unselected obstetric populations. - Conflict of interest: several authors are employees/co‑inventors/shareholders related to iPREMOM and the MaiRa test; remaining authors reported no conflicts. Data are available on request subject to ethics and data‑protection restrictions.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=vV83FyDrf2I2blSUxlgltGfnF21E8W01Kp6xGlBBuuo-1788377418.013551-1.2.1.1-6aM1oSDVRrGv6gSHrVBTn.nO2Gah5Kp7PKJcGtHRBzBvsynQpKyhIe9nC6u.3AGD) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Maternal cell-free RNA versus combined screening for first-trimester prediction of early-onset preeclampsia: a nested case-control study Elena Satorres-Perez, Nerea Castillo-Marco, Marina Igual, Teresa Cordero, Irene Munoz-Blat, Rogelio Monfort-Ortiz, Beatriz Marcos-Puig, Carlos Simon, [ View ORCID Profile](http://orcid.org/0000-0002-6584-4832)Tamara Garrido-Gomez, Alfredo Perales-Marin doi: https://doi.org/10.64898/2026.08.28.26361628 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Elena Satorres-Perez 1 Department of Obstetrics, University Hospital La Fe, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elena%2BSatorres-Perez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Satorres-Perez%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElena%2BSatorres-Perez%2B) Nerea Castillo-Marco 2 iPremom Pregnancy healthcare Diagnostics, Valencia, Spain; Carlos Simon Foundation, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nerea%2BCastillo-Marco%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Castillo-Marco%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANerea%2BCastillo-Marco%2B) Marina Igual 3 iPremom Pregnancy healthcare Diagnostics, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marina%2BIgual%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Igual%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarina%2BIgual%2B) Teresa Cordero 3 iPremom Pregnancy healthcare Diagnostics, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Teresa%2BCordero%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cordero%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATeresa%2BCordero%2B) Irene Munoz-Blat 3 iPremom Pregnancy healthcare Diagnostics, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Irene%2BMunoz-Blat%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Munoz-Blat%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIrene%2BMunoz-Blat%2B) Rogelio Monfort-Ortiz 1 Department of Obstetrics, University Hospital La Fe, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rogelio%2BMonfort-Ortiz%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Monfort-Ortiz%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARogelio%2BMonfort-Ortiz%2B) Beatriz Marcos-Puig 1 Department of Obstetrics, University Hospital La Fe, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Beatriz%2BMarcos-Puig%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marcos-Puig%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABeatriz%2BMarcos-Puig%2B) Carlos Simon 4 Carlos Simon Foundation, Valencia, Spain; Department of Obstetrics and Gynecology, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Me * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Carlos%2BSimon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Simon%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACarlos%2BSimon%2B) Tamara Garrido-Gomez 2 iPremom Pregnancy healthcare Diagnostics, Valencia, Spain; Carlos Simon Foundation, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tamara%2BGarrido-Gomez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Garrido-Gomez%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATamara%2BGarrido-Gomez%2B) * [ORCID record for Tamara Garrido-Gomez](http://orcid.org/0000-0002-6584-4832 "Open in new tab") Alfredo Perales-Marin 1 Department of Obstetrics, University Hospital La Fe, Valencia, Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alfredo%2BPerales-Marin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Perales-Marin%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlfredo%2BPerales-Marin%2B) * For correspondence: al.peralesm@comv.es * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290150/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290150/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290150/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290150/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290150/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background. In Europe, first-trimester combined screening with the Fetal Medicine Foundation (FMF) algorithm identifies women at increased risk of preeclampsia who may benefit from personalized aspirin prophylaxis. However, a substantial proportion of early-onset preeclampsia (EOPE) remains undetected at clinically acceptable specificity. Objective. To evaluate the first-trimester performance of MaiRa for early-onset preeclampsia (EOPE) risk stratification by benchmarking it against FMF screening in the same women, characterizing discordant patient-level classification profiles and exploring potential implementation strategies. Study Design. This secondary case-control analysis was nested within the prospective, multicentre PREMOM cohort [[NCT04990141](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04990141&atom=%2Fmedrxiv%2Fearly%2F2026%2F09%2F02%2F2026.08.28.26361628.atom)], which enrolled women with singleton pregnancies across 14 tertiary hospitals in Spain. First-trimester MaiRa and FMF risk estimates were evaluated in the same 126 pregnant women, comprising 99 uncomplicated controls and 27 EOPE cases, defined by disease onset before 34 weeks. Discrimination was compared using a stratified paired bootstrap analysis of the areas under the receiver-operating-characteristic curves. Performance was assessed at prespecified clinical thresholds, and detection rates were evaluated at fixed false-positive rates. Universal and contingent MaiRa implementation strategies were also evaluated. Results. MaiRa showed greater first-trimester discrimination for EOPE than FMF combined screening (AUC, 0.974 vs 0.900; P=.040) and consistently achieved higher detection rates across fixed false-positive rates. At false-positive rates of 5% and 10%, MaiRa detected 85.2% and 92.6% of EOPE cases, compared with 44.4% and 70.4% for FMF, respectively. Patient-level analysis demonstrated that MaiRa identified 12 of 27 EOPE cases (44.4%) classified as low risk by FMF; these pregnancies generally exhibited less abnormal conventional first-trimester profiles, including fewer maternal risk factors, lower mean arterial pressure and lower uterine artery pulsatility index, yet 8 of 12 (66.7%) subsequently developed severe EOPE. Exploratory implementation analyses showed that universal MaiRa screening achieved the highest EOPE detection, whereas a contingent strategy using FMF for triage and reflex MaiRa testing reduced molecular testing to 35.7% of pregnancies while maintaining 77.8% sensitivity and 97.0% specificity. Conclusion. MaiRa provided greater first-trimester discrimination for EOPE than conventional combined screening and detected additional pregnancies that later developed severe disease despite less abnormal conventional screening profiles. The findings suggest that maternal plasma cfRNA profiling captures biological alterations not fully reflected by combined first-trimester screening and support further prospective evaluation in an independent, unselected obstetric population. Key words: early-onset preeclampsia; first-trimester screening; cell-free RNA; liquid biopsy; Fetal Medicine Foundation algorithm; combined screening; risk stratification; aspirin prophylaxis. ### Competing Interest Statement N.C.-M., M.I., T.C., I.M.-B., and T.G.-G. are employees of iPREMOM. N.C-M., M.I., T.G.-G. and C.S. are named as co-inventors on a patent related to the MaiRa test. C.S. is also a shareholder of iPREMOM. The remaining authors report no conflict of interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The PREMOM study ([NCT04990141](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04990141&atom=%2Fmedrxiv%2Fearly%2F2026%2F09%2F02%2F2026.08.28.26361628.atom)) received ethical approval from the Clinical Research Ethics Committees of all participating hospitals in Spain, including CEIm Hospital Universitario y Politecnico La Fe and the corresponding ethics committees of the other 13 participating centers. The datasets used in this study had been de-identified prior to their use in the analyses reported in the manuscript. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data supporting the findings of this study are available from the corresponding authors upon reasonable request, subject to applicable ethical and data-protection restrictions. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.28.26361621v1 "An interpretable, formally verified point-of-care ultrasound risk equation for difficult videolaryngoscopy: development and internal validation") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.28.26361628.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.28.26361628v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.08.28.26361628.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Maternal cell-free RNA versus combined screening for first-trimester prediction of early-onset preeclampsia: a nested case-control study Elena Satorres-Perez, Nerea Castillo-Marco, Marina Igual, Teresa Cordero, Irene Munoz-Blat, Rogelio Monfort-Ortiz, Beatriz Marcos-Puig, Carlos Simon, Tamara Garrido-Gomez, Alfredo Perales-Marin medRxiv 2026.08.28.26361628; doi: https://doi.org/10.64898/2026.08.28.26361628 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361628v1%26text%3DMaternal%2520cell-free%2520RNA%2520versus%2520combined%2520screening%2520for%2520first-trimester%2520prediction%2520of%2520early-onset%2520preeclampsia%253A%2520a%2520nested%2520case-control%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361628v1%26t%3DMaternal%2520cell-free%2520RNA%2520versus%2520combined%2520screening%2520for%2520first-trimester%2520prediction%2520of%2520early-onset%2520preeclampsia%253A%2520a%2520nested%2520case-control%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361628v1%26title%3DMaternal%2520cell-free%2520RNA%2520versus%2520combined%2520screening%2520for%2520first-trimester%2520prediction%2520of%2520early-onset%2520preeclampsia%253A%2520a%2520nested%2520case-control%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361628v1%26title%3DMaternal%2520cell-free%2520RNA%2520versus%2520combined%2520screening%2520for%2520first-trimester%2520prediction%2520of%2520early-onset%2520preeclampsia%253A%2520a%2520nested%2520case-control%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.28.26361628) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.28.26361628v1&count=horizontal&via=&text=Maternal%20cell-free%20RNA%20versus%20combined%20screening%20for%20first-trimester%20prediction%20of%20early-onset%20preeclampsia%3A%20a%20nested%20case-control%20study&counturl=www.medrxiv.org/content/10.64898/2026.08.28.26361628v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4770) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (407) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1614) * [Epidemiology](https://www.medrxiv.org/collection/e
## Related Clinical Research

- [Health-literate hand surgery care: patient education and PROM feedback priorities from a co-design](https://medichelpline.com/clinical-feed/medrxiv-1-co-designing-health-literate-hand-surgery-care-qualitative-priorities-for.md)
- [CES-D-10 thresholds may misclassify depression in older adults: findings from ASPREE-XT](https://medichelpline.com/clinical-feed/medrxiv-21-the-measure-and-mismeasure-of-depression-in-older-adults.md)
- [Prevalence of cognitive impairment in older Palestinian adults in community and nursing homes](https://medichelpline.com/clinical-feed/plos-one-16-prevalence-of-cognitive-impairment-among-older-adult-palestinians-in-community.md)
- [Young-onset stroke in the UAE: risk factors, subtypes, and outcomes from a single-centre study](https://medichelpline.com/clinical-feed/plos-one-19-young-onset-stroke-in-the-uae-a-single-centre-retrospective-analysis-of-risk.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.